{'52WeekChange': -0.22957033,
 'SandP52WeekChange': 0.0644362,
 'address1': '9600 Blackwell Road',
 'address2': 'Suite 210',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 36.6,
 'askSize': 1200,
 'averageDailyVolume10Day': 308712,
 'averageVolume': 392065,
 'averageVolume10days': 308712,
 'beta': 1.069043,
 'beta3Year': None,
 'bid': 36.58,
 'bidSize': 1300,
 'bookValue': 11.297,
 'category': None,
 'circulatingSupply': None,
 'city': 'Rockville',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 36.9184,
 'dayLow': 35.14,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.633,
 'enterpriseToRevenue': 21.031,
 'enterpriseValue': 1093467136,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 37.398285,
 'fiftyTwoWeekHigh': 54.97,
 'fiftyTwoWeekLow': 20.03,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 27151755,
 'forwardEps': -2,
 'forwardPE': -18.29,
 'fromCurrency': None,
 'fullTimeEmployees': 257,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.14834,
 'heldPercentInstitutions': 0.92367,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/regenxbio.com',
 'longBusinessSummary': 'REGENXBIO Inc., a clinical-stage biotechnology '
                        'company, provides gene therapy product candidates to '
                        'deliver genes to cells to address genetic defects or '
                        'to enable cells in the body to produce therapeutic '
                        'proteins or antibodies that are intended to impact '
                        'disease. Its gene therapy product candidates are '
                        'based on NAV Technology Platform, a proprietary '
                        'adeno-associated virus gene delivery platform. The '
                        "company's lead product candidate is RGX-314, which is "
                        'in Phase I/IIa clinical trial for the treatment of '
                        'wet age-related macular degeneration. It is also '
                        'developing RGX-121 that is in Phase I/II clinical '
                        'trial to treat mucopolysaccharidosis type II; '
                        'RGX-111, which is in Phase I clinical trial for '
                        'treating mucopolysaccharidosis type I; RGX-181 for '
                        'the treatment of late infantile neuronal ceroid '
                        'lipofuscinosis type II disease; and RGX-501, which is '
                        'in Phase I/II clinical trials to treat homozygous '
                        'familial hypercholesterolemia. REGENXBIO Inc. also '
                        'licenses its NAV Technology Platform to other '
                        'biotechnology and pharmaceutical companies; and has a '
                        'collaboration and license agreement with Neurimmune '
                        'AG to develop vectorized antibodies for the treatment '
                        'of neurodegenerative diseases. The company was '
                        'formerly known as ReGenX Biosciences, LLC and changed '
                        'its name to REGENXBIO Inc. in September 2014. '
                        'REGENXBIO Inc. was founded in 2008 and is '
                        'headquartered in Rockville, Maryland.',
 'longName': 'REGENXBIO Inc.',
 'market': 'us_market',
 'marketCap': 1362279552,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_130641748',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -102543000,
 'nextFiscalYearEnd': 1640908800,
 'open': 36.46,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -6.41,
 'phone': '240 552 8181',
 'previousClose': 36.54,
 'priceHint': 2,
 'priceToBook': 3.238028,
 'priceToSalesTrailing12Months': 26.20121,
 'profitMargins': -1.9722501,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 36.9184,
 'regularMarketDayLow': 35.14,
 'regularMarketOpen': 36.46,
 'regularMarketPreviousClose': 36.54,
 'regularMarketPrice': 36.46,
 'regularMarketVolume': 329926,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 37186200,
 'sharesPercentSharesOut': 0.114700004,
 'sharesShort': 4272707,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4157713,
 'shortName': 'REGENXBIO Inc.',
 'shortPercentOfFloat': 0.1822,
 'shortRatio': 9.47,
 'startDate': None,
 'state': 'MD',
 'strikePrice': None,
 'symbol': 'RGNX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.781,
 'twoHundredDayAverage': 39.27572,
 'volume': 329926,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.regenxbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '20850'}